Skip to main content
SpringerLink
Log in
Book cover

Stereotactic Radiosurgery and Stereotactic Body Radiation Therapy pp 289–305Cite as

SAbR for Primary Prostate Cancer

  • Chapter
  • First Online:

  • 1361 Accesses

Abstract

Radiation therapy is a standard treatment option for all stages of prostate cancer. Improvements in imaging and radiation delivery technology have facilitated excellent outcomes with extended courses of conventionally fractionated (1.8–2.0 Gy/fraction) radiation therapy and more recently equivalent outcomes with moderately hypofractionated (2.25–4 Gy/fraction) courses. There is strong evidence that even higher dose hypofractionated regimens (6–10 Gy/fraction), or “oligofractionation” delivered using stereotactic ablative body radiosurgery (SAbR; also referred to as stereotactic body radiation therapy, SBRT), may offer additional clinical benefits, with increased likelihood of durable biochemical control, patient convenience, and possible reduction in cost of care. Recent clinical trials have shown excellent outcomes in appropriately selected patients treated with advanced modern techniques and technology. This chapter will discuss the rationale, clinical experience, and techniques for optimal application of SAbR in the management of localized prostate cancer.

This is a preview of subscription content, log in via an institution.

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   89.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD   119.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD   169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

References

  1. Lloyd-Davies RW, Collins CD, Swan AV. Carcinoma of prostate treated by radical external beam radiotherapy using hypofractionation. Twenty-two years’ experience (1962-1984). Urology. 1990;36(2):107–11.

    Article  CAS  Google Scholar 

  2. Hodges JC, Lotan Y, Boike TP, Benton R, Barrier A, Timmerman RD. Cost-effectiveness analysis of stereotactic body radiation therapy versus intensity-modulated radiation therapy: an emerging initial radiation treatment option for organ-confined prostate cancer. J Oncol Pract. 2012;8(3 Suppl):e31s–7s.

    Article  Google Scholar 

  3. Parthan A, Pruttivarasin N, Davies D, Taylor DC, Pawar V, Bijlani A, et al. Comparative cost-effectiveness of stereotactic body radiation therapy versus intensity-modulated and proton radiation therapy for localized prostate cancer. Front Oncol. 2012;2:81.

    Article  CAS  Google Scholar 

  4. Brenner DJ, Martinez AA, Edmundson GK, Mitchell C, Thames HD, Armour EP. Direct evidence that prostate tumors show high sensitivity to fractionation (low alpha/beta ratio), similar to late-responding normal tissue. Int J Radiat Oncol Biol Phys. 2002;52(1):6–13.

    Article  Google Scholar 

  5. Miralbell R, Roberts SA, Zubizarreta E, Hendry JH. Dose-fractionation sensitivity of prostate cancer deduced from radiotherapy outcomes of 5,969 patients in seven international institutional datasets: alpha/beta = 1.4 (0.9-2.2) Gy. Int J Radiat Oncol Biol Phys. 2012;82(1):e17–24.

    Article  Google Scholar 

  6. Pedicini P, Caivano R, Strigari L, Benassi M, Fiorentino A, Fusco V. In regard to Miralbell, et al. Re: Dose-fractionation sensitivity of prostate cancer deduced from radiotherapy outcomes of 5969 patients in seven international institutional datasets: alpha/beta=1.4 (0.9-2.2) Gy. Int J Radiat Oncol Biol Phys. 2013;85(1):10–1.

    Article  Google Scholar 

  7. Vogelius IR, Bentzen SM. Meta-analysis of the alpha/beta ratio for prostate cancer in the presence of an overall time factor: bad news, good news, or no news? Int J Radiat Oncol Biol Phys. 2013;85(1):89–94.

    Article  Google Scholar 

  8. Marzi S, Saracino B, Petrongari MG, Arcangeli S, Gomellini S, Arcangeli G, et al. Modeling of alpha/beta for late rectal toxicity from a randomized phase II study: conventional versus hypofractionated scheme for localized prostate cancer. J Exp Clin Cancer Res. 2009;28:117.

    Article  Google Scholar 

  9. Thames HD, Bentzen SM, Turesson I, Overgaard M, Van den Bogaert W. Time-dose factors in radiotherapy: a review of the human data. Radiother Oncol. 1990;19(3):219–35.

    Article  CAS  Google Scholar 

  10. Douglas BG, Fowler JF. The effect of multiple small doses of x rays on skin reactions in the mouse and a basic interpretation. Radiat Res. 1976;66(2):401–26.

    Article  CAS  Google Scholar 

  11. Park C, Papiez L, Zhang S, Story M, Timmerman RD. Universal survival curve and single fraction equivalent dose: useful tools in understanding potency of ablative radiotherapy. Int J Radiat Oncol Biol Phys. 2008;70(3):847–52.

    Article  Google Scholar 

  12. Arcangeli G, Saracino B, Arcangeli S, Gomellini S, Petrongari MG, Sanguineti G, et al. Moderate hypofractionation in high-risk, organ-confined prostate cancer: final results of a phase III randomized trial. J Clin Oncol. 2017;35(17):1891–7.

    Article  CAS  Google Scholar 

  13. Dearnaley D, Syndikus I, Mossop H, Khoo V, Birtle A, Bloomfield D, et al. Conventional versus hypofractionated high-dose intensity-modulated radiotherapy for prostate cancer: 5-year outcomes of the randomised, non-inferiority, phase 3 CHHiP trial. Lancet Oncol. 2016;17(8):1047–60.

    Article  Google Scholar 

  14. Lee WR, Dignam JJ, Amin MB, Bruner DW, Low D, Swanson GP, et al. Randomized phase III noninferiority study comparing two radiotherapy fractionation schedules in patients with low-risk prostate cancer. J Clin Oncol. 2016;34(20):2325–32.

    Article  Google Scholar 

  15. Catton CN, Lukka H, Gu CS, Martin JM, Supiot S, Chung PWM, et al. Randomized trial of a hypofractionated radiation regimen for the treatment of localized prostate cancer. J Clin Oncol. 2017;35(17):1884–90.

    Article  CAS  Google Scholar 

  16. Incrocci L, Wortel RC, Alemayehu WG, Aluwini S, Schimmel E, Krol S, et al. Hypofractionated versus conventionally fractionated radiotherapy for patients with localised prostate cancer (HYPRO): final efficacy results from a randomised, multicentre, open-label, phase 3 trial. Lancet Oncol. 2016;17(8):1061–9.

    Article  Google Scholar 

  17. Aluwini S, Pos F, Schimmel E, Krol S, van der Toorn PP, de Jager H, et al. Hypofractionated versus conventionally fractionated radiotherapy for patients with prostate cancer (HYPRO): late toxicity results from a randomised, non-inferiority, phase 3 trial. Lancet Oncol. 2016;17(4):464–74.

    Article  Google Scholar 

  18. Pollack A, Walker G, Horwitz EM, Price R, Feigenberg S, Konski AA, et al. Randomized trial of hypofractionated external-beam radiotherapy for prostate cancer. J Clin Oncol. 2013;31(31):3860–8.

    Article  Google Scholar 

  19. Madsen BL, Hsi RA, Pham HT, Fowler JF, Esagui L, Corman J. Stereotactic hypofractionated accurate radiotherapy of the prostate (SHARP), 33.5 Gy in five fractions for localized disease: first clinical trial results. Int J Radiat Oncol Biol Phys. 2007;67(4):1099–105.

    Article  Google Scholar 

  20. King CR, Brooks JD, Gill H, Presti JC Jr. Long-term outcomes from a prospective trial of stereotactic body radiotherapy for low-risk prostate cancer. Int J Radiat Oncol Biol Phys. 2012;82(2):877–82.

    Article  Google Scholar 

  21. Katz AJ, Santoro M, Diblasio F, Ashley R. Stereotactic body radiotherapy for localized prostate cancer: disease control and quality of life at 6 years. Radiat Oncol. 2013;8:118.

    Article  CAS  Google Scholar 

  22. Katz AJ, Kang J. Stereotactic body radiotherapy as treatment for organ confined low- and intermediate-risk prostate carcinoma, a 7-year study. Front Oncol. 2014;4:240.

    PubMed  PubMed Central  Google Scholar 

  23. Jackson WC, Dess RT, Litzenberg DW, Li P, Schipper M, Rosenthal SA, et al. A multi-institutional phase II trial of prostate stereotactic body radiation therapy (SBRT) utilizing continuous real-time evaluation of prostate motion with patient reported quality of life. Practical Radiation Oncology. 2018;8(1):40–7.

    Article  Google Scholar 

  24. Mantz C. A phase II trial of stereotactic ablative body radiotherapy for low-risk prostate cancer using a non-robotic linear accelerator and real-time target tracking: report of toxicity, quality of life, and disease control outcomes with 5-year minimum follow-up. Front Oncol. 2014;4:279.

    Article  Google Scholar 

  25. Zelefsky MJ, Kollmeier MA, McBride S, Pei X, Happersett L, Lin M, et al. 5-year outcomes of a phase 1 dose escalation study using stereotactic body radiosurgery for patients with clinically localized prostate cancer. Int J Radiat Oncol Biol Phys. 2017;99(2):S156–S7.

    Article  Google Scholar 

  26. King CR, Collins S, Fuller D, Wang PC, Kupelian P, Steinberg M, et al. Health-related quality of life after stereotactic body radiation therapy for localized prostate cancer: results from a multi-institutional consortium of prospective trials. Int J Radiat Oncol Biol Phys. 2013;87(5):939–45.

    Article  Google Scholar 

  27. King CR, Freeman D, Kaplan I, Fuller D, Bolzicco G, Collins S, et al. Stereotactic body radiotherapy for localized prostate cancer: pooled analysis from a multi-institutional consortium of prospective phase II trials. Radiother Oncol. 2013;109(2):217–21.

    Article  Google Scholar 

  28. Freeman D, Dickerson G, Perman M. Multi-institutional registry for prostate cancer radiosurgery: a prospective observational clinical trial. Front Oncol. 2014;4:369.

    PubMed  Google Scholar 

  29. Lotan Y, Stanfield J, Cho LC, Sherwood JB, Abdel-Aziz KF, Chang CH, et al. Efficacy of high dose per fraction radiation for implanted human prostate cancer in a nude mouse model. J Urol. 2006;175(5):1932–6.

    Article  Google Scholar 

  30. Boike TP, Lotan Y, Cho LC, Brindle J, DeRose P, Xie XJ, et al. Phase I dose-escalation study of stereotactic body radiation therapy for low- and intermediate-risk prostate cancer. J Clin Oncol. 2011;29(15):2020–6.

    Article  Google Scholar 

  31. Kim DW, Cho LC, Straka C, Christie A, Lotan Y, Pistenmaa D, et al. Predictors of rectal tolerance observed in a dose-escalated phase 1-2 trial of stereotactic body radiation therapy for prostate cancer. Int J Radiat Oncol Biol Phys. 2014;89(3):509–17.

    Article  Google Scholar 

  32. Hannan R, Tumati V, Xie XJ, Cho LC, Kavanagh BD, Brindle J, et al. Stereotactic body radiation therapy for low and intermediate risk prostate cancer-results from a multi-institutional clinical trial. Eur J Cancer. 2016;59:142–51.

    Article  Google Scholar 

  33. Kim DN, Straka C, Cho LC, Lotan Y, Yan J, Kavanagh B, et al. Early and multiple PSA bounces can occur following high-dose prostate stereotactic body radiation therapy: subset analysis of a phase 1/2 trial. Pract Radiat Oncol. 2017;7(1):e43–e9.

    Article  Google Scholar 

  34. Folkert MR, Zelefsky MJ, Hannan R, Desai NB, Lotan Y, Laine AM, et al. Multi-institutional phase 2 trial of high-dose stereotactic body radiation therapy with temporary hydrogel spacer for low- and intermediate-risk prostate cancer. Int J Radiat Oncol Biol Phys. 2017;99(5):1319–20.

    Article  Google Scholar 

  35. Hamstra DA, Mariados N, Sylvester J, Shah D, Karsh L, Hudes R, et al. Continued benefit to rectal separation for prostate radiation therapy: final results of a phase III trial. Int J Radiat Oncol Biol Phys. 2017;97(5):976–85.

    Article  Google Scholar 

  36. Mariados N, Sylvester J, Shah D, Karsh L, Hudes R, Beyer D, et al. Hydrogel spacer prospective multicenter randomized controlled pivotal trial: dosimetric and clinical effects of perirectal spacer application in men undergoing prostate image guided intensity modulated radiation therapy. Int J Radiat Oncol Biol Phys. 2015;92(5):971–7.

    Article  Google Scholar 

  37. Jones RT, Hassan Rezaeian N, Desai NB, Lotan Y, Jia X, Hannan R, et al. Dosimetric comparison of rectal-sparing capabilities of rectal balloon vs injectable spacer gel in stereotactic body radiation therapy for prostate cancer: lessons learned from prospective trials. Med Dosim. 2017;42(4):341–7.

    Article  Google Scholar 

  38. Jacobs BL, Yabes JG, Lopa SH, Heron DE, Chang CH, Schroeck FR, et al. The early adoption of intensity-modulated radiotherapy and stereotactic body radiation treatment among older Medicare beneficiaries with prostate cancer. Cancer. 2017;123(15):2945–54.

    Article  Google Scholar 

  39. Arcangeli S, Greco C. Hypofractionated radiotherapy for organ-confined prostate cancer: is less more? Nat Rev Urol. 2016;13(7):400–8.

    Article  CAS  Google Scholar 

  40. Morris WJ, Tyldesley S, Rodda S, Halperin R, Pai H, McKenzie M, et al. Androgen Suppression Combined with Elective Nodal and Dose Escalated Radiation Therapy (the ASCENDE-RT Trial): an analysis of survival endpoints for a randomized trial comparing a low-dose-rate brachytherapy boost to a dose-escalated external beam boost for high- and intermediate-risk prostate cancer. Int J Radiat Oncol Biol Phys. 2017;98(2):275–85.

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. University of Texas Southwestern Medical Center, Department of Radiation Oncology, Dallas, TX, USA

    Michael R. Folkert & Neil B. Desai

  2. University of Texas Southwestern Medical Center, Departments of Radiation Oncology and Immunology, Dallas, TX, USA

    Raquibul Hannan

  3. University of Texas Southwestern Medical Center, Departments of Radiation Oncology and Neurological Surgery, Dallas, TX, USA

    Robert D. Timmerman

Authors
  1. Michael R. Folkert
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Raquibul Hannan
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Neil B. Desai
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Robert D. Timmerman
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Robert D. Timmerman .

Editor information

Editors and Affiliations

  1. Mayo Clinic, Radiation Oncology, Mayo Clinic School of Medicine Radiation Oncology, Jacksonville, FL, USA

    Daniel M. Trifiletti

  2. Department of Radiation Oncology, Rose Ella Burkhardt Brain Tumor and Neuro-Oncology Center, Cleveland Clinic, Cleveland, OH, USA

    Samuel T. Chao

  3. Sunnybrook Odette Cancer Centre, Department of Radiation Oncology, University of Toronto, Toronto, ON, Canada

    Arjun Sahgal

  4. University of Virginia, Departments of Neurological Surgery and Radiation Oncology, Charlottesville, VA, USA

    Jason P. Sheehan

Rights and permissions

Reprints and permissions

Copyright information

© 2019 Springer Nature Switzerland AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Folkert, M.R., Hannan, R., Desai, N.B., Timmerman, R.D. (2019). SAbR for Primary Prostate Cancer. In: Trifiletti, D., Chao, S., Sahgal, A., Sheehan, J. (eds) Stereotactic Radiosurgery and Stereotactic Body Radiation Therapy. Springer, Cham. https://doi.org/10.1007/978-3-030-16924-4_25

Download citation

  • DOI: https://doi.org/10.1007/978-3-030-16924-4_25

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-030-16923-7

  • Online ISBN: 978-3-030-16924-4

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation